scholarly journals Eurycoma longifolia: Medicinal Plant in the Prevention and Treatment of Male Osteoporosis due to Androgen Deficiency

2012 ◽  
Vol 2012 ◽  
pp. 1-9 ◽  
Author(s):  
Nadia Mohd Effendy ◽  
Norazlina Mohamed ◽  
Norliza Muhammad ◽  
Isa Naina Mohamad ◽  
Ahmad Nazrun Shuid
Keyword(s):  
Medicinal Plant ◽  
Male Osteoporosis ◽  
Testosterone Replacement Therapy ◽  
Androgen Deficiency ◽  
Elderly Men ◽  
Eurycoma Longifolia ◽  
Major Factors ◽  
Phytochemical Components ◽  
Reduce Bone Loss ◽  
Osteoclast Apoptosis

Osteoporosis in elderly men is now becoming an alarming health issue due to its relation with a higher mortality rate compared to osteoporosis in women. Androgen deficiency (hypogonadism) is one of the major factors of male osteoporosis and it can be treated with testosterone replacement therapy (TRT). However, one medicinal plant,Eurycoma longifoliaJack (EL), can be used as an alternative treatment to prevent and treat male osteoporosis without causing the side effects associated with TRT.ELexerts proandrogenic effects that enhance testosterone level, as well as stimulate osteoblast proliferation and osteoclast apoptosis. This will maintain bone remodelling activity and reduce bone loss. Phytochemical components ofELmay also prevent osteoporosis via its antioxidative property. Hence,ELhas the potential as a complementary treatment for male osteoporosis.

Correction of Androgen Deficiency in Men with Type 2 Diabetes

2021 ◽  
Vol 16 ◽  
Author(s):  
Volodymyr Pankiv ◽  
Tetyana Yuzvenko ◽  
Nazarii Kobyliak ◽  
Ivan Pankiv
Keyword(s):  
Type 2 Diabetes ◽  
Replacement Therapy ◽  
Testosterone Replacement ◽  
Control Group ◽  
Total Testosterone ◽  
Testosterone Replacement Therapy ◽  
Androgen Deficiency ◽  
Testosterone Undecanoate ◽  
Testosterone Levels

Background: In men with low levels of testosterone in the blood, it is believed that the symptoms can be regarded as an association between testosterone deficiency syndrome and related comorbidities. Aim: to investigate the effectiveness of testosterone therapy in patients with type 2 diabetes (T2D) and androgen deficiency. Materials and methods: Testosterone replacement therapy was carried out in 26 men with T2D and clinically or laboratory-confirmed androgen deficiency. The age of the subjects ranged from 35 to 69 years old. Laboratory studies included determinations of the concentration of the hormones estradiol, luteinizing hormone (LH), and prostate-specific antigen (PSA). The observation period was 9 months. Results: The average level of total blood testosterone in the subjects before treatment was 9.4 mol/l and was likely lower than that of the control group (19.3 ± 1.6 nmol/l). The levels of total testosterone in the subjects ranged from 3.9 nmol/l to 10.7 nmol/l, and hormone levels measuring less than 8.0 nmol/l were observed in only 11 patients. After a course of testosterone replacement therapy, a stabilization in total testosterone levels at the level of reference values (as compared to the start of treatment) was observed in the blood of men with T2D after 9 months of observation and the administration of the fourth injection (16.83 ± 0.75 nmol/l). Conclusion: The use of long-acting injectable testosterone undecanoate leads to normalization of total testosterone levels in the blood of men with T2D and androgen deficiency, and LH levels in these patients are unlikely to change.

scholarly journals Management of Osteoporosis in Men: A Narrative Review

2021 ◽  
Vol 22 (24) ◽  
pp. 13640
Author(s):  
Fabio Vescini ◽  
Iacopo Chiodini ◽  
Alberto Falchetti ◽  
Andrea Palermo ◽  
Antonio Stefano Salcuni ◽  
...  
Keyword(s):  
Pathological Condition ◽  
Osteoporotic Fractures ◽  
Clinical History ◽  
Bone Fragility ◽  
Pharmacological Therapy ◽  
Male Osteoporosis ◽  
Testosterone Replacement Therapy ◽  
Mineral Density ◽  
Bmd Testing ◽  
Follicle Stimulating Hormones

Male osteoporosis is a still largely underdiagnosed pathological condition. As a consequence, bone fragility in men remains undertreated mainly due to the low screening frequency and to controversies in the bone mineral density (BMD) testing standards. Up to the 40% of overall osteoporotic fractures affect men, in spite of the fact that women have a significant higher prevalence of osteoporosis. In addition, in males, hip fractures are associated with increased morbidity and mortality as compared to women. Importantly, male fractures occur about 10 years later in life than women, and, therefore, due to the advanced age, men may have more comorbidities and, consequently, their mortality is about twice the rate in women. Gender differences, which begin during puberty, lead to wider bones in males as compared with females. In men, follicle-stimulating hormones, testosterone, estrogens, and sex hormone-binding levels, together with genetic factors, interact in determining the peak of bone mass, BMD maintenance, and lifetime decrease. As compared with women, men are more frequently affected by secondary osteoporosis. Therefore, in all osteoporotic men, a complete clinical history should be collected and a careful physical examination should be done, in order to find clues of a possible underlying diseases and, ultimately, to guide laboratory testing. Currently, the pharmacological therapy of male osteoporosis includes aminobisphosphonates, denosumab, and teriparatide. Hypogonadal patients may be treated with testosterone replacement therapy. Given that the fractures related to mortality are higher in men than in women, treating male subjects with osteoporosis is of the utmost importance in clinical practice, as it may impact on mortality even more than in women.

scholarly journals Microsatellite markers of an important medicinal plant, Eurycoma longifolia (Simaroubaceae), for DNA profiling

2011 ◽  
Vol 98 (5) ◽  
pp. e130-e132 ◽  
Author(s):  
L. H. Tnah ◽  
C. T. Lee ◽  
S. L. Lee ◽  
K. K. S. Ng ◽  
C. H. Ng ◽  
...  
Keyword(s):  
Medicinal Plant ◽  
Microsatellite Markers ◽  
Dna Profiling ◽  
Eurycoma Longifolia ◽  
Important Medicinal Plant

Corrigendum to “In vitro anti-tumor promoting and anti-parasitic activities of the quassinoids from Eurycoma longifolia, a medicinal plant in Southeast Asia”

2003 ◽  
Vol 85 (1) ◽  
pp. 173 ◽  
Author(s):  
Suratwadee Jiwajinda ◽  
Vilai Santisopasri ◽  
Akira Murakami ◽  
Masanori Kawanaka ◽  
Hiromu Kawanaka ◽  
...  
Keyword(s):  
Medicinal Plant ◽  
Southeast Asia ◽  
Eurycoma Longifolia

scholarly journals Comparative antimicrobial studies on plant species known as ’Pasak Bumi': Eurycoma longifolia Jack., Rennelia elliptica Korth. and Trivalvaria macrophylla miq.

F1000Research ◽  
2019 ◽  
Vol 8 ◽  
pp. 301
Author(s):  
Harlinda Kuspradini ◽  
Sisilia Silau ◽  
Supartini Supartini ◽  
Enih Rosamah ◽  
Keyword(s):  
Medicinal Plant ◽  
Plant Species ◽  
Activity Index ◽  
Ethanol Extract ◽  
Antimicrobial Activities ◽  
Diffusion Method ◽  
Phenol Content ◽  
Streptococcus Sobrinus ◽  
Eurycoma Longifolia ◽  
Antimicrobial Studies

Pasak Bumi is a local name for a medicinal plant in Kalimantan, Indonesia. It is a famous medicinal plant and commonly used in traditional medicine as an aphrodisiac, as well as in the treatment of malaria. Pasak Bumi is a commercial name for Eurycoma longifolia (Simaroubaceae) plant species. Besides Eurycoma longifolia there are two other plant species also known locally as Pasak Bumi, Rennelia elliptica (Rubiaceae) and Trivalvaria macrophylla (Annonaceae). This study was performed to investigate the antimicrobial activities of the different species of Pasak Bumi and its total phenol contents. The antimicrobial activity of the ethanol extract was determined using the Agar Well Diffusion method at various concentrations while the phenol content was determined by the Folin - Ciocalteu method. The results of the ethanol extract from the different root showed that the T. macrophylla had the highest phenol content, and the highest activity index (AI) was found in the E. longifolia (0.96 at 1000 µg concentration). The results of this study show that the three different Pasak Bumi have potential as antimicrobials against oral pathogen; 1 yeast: Candida albicans, and 3 bacterias: Staphylococcus aureus, Streptococcus mutans, and Streptococcus sobrinus.

scholarly journals State of lipid metabolism in patients receiving androgen replacement therapy

2021 ◽  
Vol 37 (5) ◽  
pp. 20-26
Author(s):  
P. S. Popov ◽  
I. A. Kournikova ◽  
V. I. Torshin ◽  
N. N. Malyutina
Keyword(s):  
Cardiovascular Risk ◽  
Lipid Metabolism ◽  
Replacement Therapy ◽  
Negative Impact ◽  
Modern Medicine ◽  
Testosterone Replacement Therapy ◽  
Androgen Deficiency ◽  
Androgen Replacement Therapy ◽  
Individual Adjustment ◽  
Dose Dependent

Objective. To assess the state of lipid metabolism indicators and predict cardiovascular risk in patients with secondary (acquired) hypogonadism on the background of androgen replacement therapy. Testosterone replacement therapy is often used in modern medicine for diagnosed androgen deficiency in patients of any age group. There are quite a lot of publications devoted to diagnosis and treatment, but the effectiveness and safety of any therapy is determined by several factors, of which two were considered in the presented study dose-dependent effect and compliance. Material and methods. Sixty two patients aged 30 to 52 years with androgen deficiency and a low risk of developing cardiovascular diseases were examined according to the Princeton Consensus criteria. Patients were divided into groups depending on the severity of androgen deficiency and the duration of therapy. Complaints, objective status, muscle strength, daily blood pressure and heart rate monitoring data, lipidogram and sex hormone indicators were evaluated. Results. The obtained data suggest that androgen replacement therapy in doses that lead to an increase in the level of testosterone in the blood above the upper limit of reference values had a negative impact on the lipid spectrum and increased cardiovascular risk for this group of patients. Conclusions. The analyzed approach to therapy of androgen deficiency should provide an individual adjustment of dosage on the background of determining the target blood testosterone level.

Sign in / Sign up

Export Citation Format

Share Document